Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODE Study of CER-001 in homozygous familial hypercholesterolemia
NL-OMON39438Phase 2Active, not recruiting
- Sponsor
- ABIONYX Pharma
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in homozygous familial hypercholesterolemia (HoFH), sponsored by ABIONYX Pharma. Primary endpoint: Percent change from baseline to follow-up in carotid mean vessel wall area. Started Apr 2012; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON39438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39438.